OpenNeedle Ask your own

Question explored with the scientific record

Answered on this page ↓

Could 48 hours by theoretically plausible? How?

Sep 17, 2026 · 3 sources used · OpenNeedle synthesis
The short version: 48 hours is biologically plausible for some mechanisms, but the retrieved evidence does not document a single case with that onset.

The strongest documented case in these records is the IFNAR2-deficient child who died of encephalitis after MMR, with measles, mumps, rubella, and HHV6 all detected [1]. That proves live vaccine virus can reach the brain and kill in an immune-compromised host, but the study reports no day-by-day onset. For a healthy child, the classic teaching is that live-virus encephalitis follows the viral replication cycle, which typically takes 5 to 15 days after MMR [2]. A 48-hour onset would be unusually fast for that mechanism.

But there are other mechanisms that could act within 48 hours. An immediate hypersensitivity or autoimmune reaction to vaccine components, including the aluminum adjuvant, does not need viral replication. It can begin within hours to a couple of days. The same applies to Hep A, which is an inactivated vaccine and cannot replicate at all; any encephalitis after it would have to be immune-mediated, and that could plausibly start fast. The records do not contain a controlled study mapping onset times for these reactions, and the passive surveillance systems that would catch such cases detect almost nothing by design [3].

The honest answer: 48 hours is biologically plausible for an immune-mediated reaction, but not for the classic live-virus replication timeline, and no retrieved study documents a case at that onset. The evidence base is too thin to rule it in or out.

My call: 48 hours is theoretically plausible but unproven, and the evidence does not establish it as a documented timeline. Confidence: low.

Keep digging

Sources used 3

  1. Human IFNAR2 deficiency: Lessons for antiviral immunity Science Translational Medicine (2015) Thin

    This study identifies a homozygous mutation in the IFNAR2 gene in a child with fatal encephalitis following MMR vaccination, highlighting the critical role of type I interferons in human antiviral immunity.

    DOI: 10.1126/scitranslmed.aac4227
  2. MMR vaccine - how effective and how safe? Drug and Therapeutics Bulletin (2003) narrative review Strong

    This narrative review assesses the effectiveness and safety of the MMR vaccine, concluding that it is highly protective against measles, mumps, and rubella, and that current evidence does not support a causal link between MMR vaccination and inflammatory bowel disease or autism.

    DOI: 10.1136/dtb.2003.41425
  3. Surveillance of adverse events following immunisation in Australia annual report, 2022 Communicable Diseases Intelligence (2025) Thin

    A national registry-based analysis of non-COVID-19 adverse events following immunisation (AEFI) in Australia for 2022, detailing demographic patterns, reporting sources, vaccine-associated adverse events, signals (notably hypersensitivity and vaccination errors), the impact of n…

    DOI: 10.33321/cdi.2025.49.043

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question